Chartwell Investment Partners’s bluebird bio BLUE Stock Holding History

Chartwell Investment Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-707	Closed	-$1.44M	–	472
2018 Q2	$1.44M	Sell	707 -27	-4%	-$61.5K	0.04%	418
2018 Q1	$1.62M	Sell	734 -14	-2%	-$35.6K	0.06%	321
2017 Q4	$1.73M	Sell	748 -292	-28%	-$593K	0.06%	345
2017 Q3	$1.85M	Buy	1,040 +291	+39%	+$407K	0.06%	333
2017 Q2	$1.02M	Buy	749 +1	+0.1%	+$1.21K	0.04%	350
2017 Q1	$881K	Sell	748 -429	-36%	-$438K	0.03%	351
2016 Q4	$940K	Sell	1,177 -2,046	-63%	-$1.62M	0.03%	371
2016 Q3	$2.83M	Buy	+3,223	New	+$2.33M	0.05%	321

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chartwell Investment Partners's BLUE Position: Q3 2018 in Review

Chartwell Investment Partners sold out of bluebird bio (BLUE) in Q3 2018, closing a stake of 707 shares — an estimated $1.44M sold.

Chartwell Investment Partners first reported a position in BLUE in Q3 2016 and held it in 8 quarters. The position peaked at $2.83M in Q3 2016. 288 funds tracked by Wall St. Rank hold BLUE as of Q3 2018.

Chartwell Investment Partners reported no remaining bluebird bio position as of Q3 2018 after selling out during the quarter.
Chartwell Investment Partners sold 707 bluebird bio shares in Q3 2018, an estimated $1.44M.
Chartwell Investment Partners first reported a position in bluebird bio in Q3 2016 and held it in 8 quarters.
Chartwell Investment Partners's bluebird bio position peaked at $2.83M in Q3 2016.
288 funds tracked by Wall St. Rank held bluebird bio as of Q3 2018.

Based on Chartwell Investment Partners's 13F filing for Q3 2018, filed 8 Nov 2018.